Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Phase 2 trial: the study that started it all The Phase 2 trial, published in the New England Journal of Medicine under the title "Triple Hormone Receptor Agonist Retatrutide for Obesity," is the foundation upon which the entire Phase 3 program was built
This trial accorded with the ethical principles of the Declaration of Helsinki and was consistent with the International Conference on Harmonization of Good Clinical Practice and applicable regulatory requirements
GLP-1 medications are titrated over time for good reason moving too quickly to a higher dose before the body adjusts can amplify side effects including fatigue
The positive response along with the triple agonist mechanism of retatrutide makes it a breakthrough drug in the recent weight-loss battle
Research grade, 98% purity
)
